Top Page
Staar Surgical
(NASDAQ:STAA)
Staar Surgical (STAA) vs. SPDR S&P 500 ETF (SPY)
Staar Surgical Business Overview & Revenue Model
Staar Surgical Key Performance Indicators (KPIs)
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
The FlyStaar Surgical Earnings Call Summary
Staar Surgical Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 239.44M | 313.90M | 322.42M | 284.39M | 230.47M |
| Gross Profit | 176.90M | 239.58M | 252.65M | 223.38M | 178.64M |
| EBITDA | -37.18M | -5.72M | 33.22M | 48.31M | 36.98M |
| Net Income | -80.45M | -20.21M | 21.35M | 39.66M | 27.51M |
Balance Sheet | |||||
| Total Assets | 451.68M | 509.52M | 488.69M | 418.82M | 345.78M |
| Cash, Cash Equivalents and Short-Term Investments | 153.15M | 230.49M | 220.73M | 211.64M | 199.71M |
| Total Debt | 38.35M | 38.74M | 35.83M | 31.04M | 32.06M |
| Total Liabilities | 107.49M | 112.19M | 102.74M | 82.71M | 87.22M |
| Stockholders Equity | 344.18M | 397.33M | 385.95M | 336.11M | 258.56M |
Cash Flow | |||||
| Free Cash Flow | -40.05M | -7.67M | -3.59M | 17.61M | 30.32M |
| Operating Cash Flow | -34.23M | 15.72M | 14.59M | 35.72M | 43.96M |
| Investing Cash Flow | 46.34M | -59.22M | 74.35M | -156.38M | -13.64M |
| Financing Cash Flow | -4.55M | 5.72M | 7.42M | 8.30M | 17.79M |
Staar Surgical Technical Analysis
Staar Surgical Risk Analysis
Staar Surgical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $14.52B | 30.60 | 4.83% | ― | 5.06% | -4.47% | |
66 Neutral | $16.86B | 23.34 | 11.01% | ― | 1.74% | -25.29% | |
63 Neutral | $9.16B | -45.07 | -17.21% | ― | -16.03% | -813.48% | |
63 Neutral | $4.11B | 24.79 | 9.72% | 0.29% | 9.19% | 23.06% | |
60 Neutral | $6.07B | -16.79 | -4.69% | ― | 6.23% | 17.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $853.10M | -14.54 | -23.24% | ― | -32.42% | -540.37% |
Staar Surgical Corporate Events
On March 3, 2026, STAAR Surgical reported fourth quarter 2025 net sales of $57.8 million, up 18.1% year over year, driven mainly by China, while sales excluding China slipped 2.1% and quarterly adjusted EBITDA reached breakeven. Gross margin improved sharply to 75.7%, but the company still posted a quarterly net loss of $18.3 million, partly reflecting merger-termination and restructuring costs, although underlying operating expenses fell once those items were excluded.
For full-year 2025, net sales declined 23.7% to $239.4 million due to channel inventory reductions in China, even as revenue outside China grew 6.6% and gross margin held steady at 76.2%. STAAR recorded a wider annual net loss of $80.4 million and an adjusted EBITDA loss of $6.6 million, but management highlighted normalized inventories and recovering in‑market demand in China, a successful EVO+ ICL launch, and recent leadership changes and cost controls as setting a clearer path to sustainable profitability and renewed growth as a standalone company.
The most recent analyst rating on (STAA) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
On February 4, 2026, STAAR Surgical Company entered into a letter agreement with Chief Legal Officer and Corporate Secretary Nathaniel Sisitsky providing for his termination of employment, which is being treated as a termination without cause, effective that same date. Concurrently, the company entered into a consulting agreement under which Sisitsky will provide transition-related legal consulting services through March 13, 2026, in exchange for weekly consulting fees and a potential completion fee. Under the terms aligned with his existing severance agreement, Sisitsky is eligible to receive 12 months of base salary and continued benefits coverage, subject to a general release, as well as his 2025 annual bonus and a remaining $75,000 cash recognition and retention award installment. Restricted stock units scheduled to vest in March 2026 were accelerated and vested as of his separation, while his other unvested equity awards and options were forfeited, signaling a managed leadership transition in the legal function with defined financial and equity arrangements for the departing executive.
The most recent analyst rating on (STAA) stock is a Sell with a $20.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
On February 1, 2026, STAAR Surgical’s board appointed President and Chief Operating Officer Warren Foust and Chief Financial Officer Deborah Andrews as interim co-chief executive officers, following the previously announced resignation of CEO Stephen C. Farrell effective January 31, 2026. The board has formed a search committee that has already launched a global process to identify a permanent chief executive, considering both internal and external candidates, while Foust and Andrews continue in their existing roles and assume shared responsibility for leading day-to-day operations. As part of the transition, the board approved restricted stock unit awards valued at $375,000 each for Foust and Andrews, with additional protections and potential accelerated vesting for Foust under a new letter agreement if he is not ultimately selected as CEO or is terminated under specified conditions, underscoring the company’s effort to maintain leadership stability and retain key executives during a period of governance change prompted by its recent cooperation agreement with Broadwood Partners.
The most recent analyst rating on (STAA) stock is a Sell with a $20.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
On January 15, 2026, STAAR Surgical Company’s board elected Neal C. Bradsher, founder and president of Broadwood Capital, Inc., as Board Chair and restructured the leadership and composition of its three standing committees—Audit, Compensation, and Nominating and Governance—so that each is now chaired and populated by directors the board has determined to be independent under NASDAQ rules, restoring the company’s compliance with NASDAQ’s Audit Committee independence requirements and ending its cure period. On the same date, the board created two new committees: a Search Committee tasked with guiding leadership decisions, including the process to identify a successor to the Chief Executive Officer, and an Insight and Engagement Committee designed to strengthen interaction with management, stakeholders and industry experts, with board members, including the new chair, eligible for additional compensation for these expanded governance responsibilities under the existing non-employee director compensation program.
The most recent analyst rating on (STAA) stock is a Sell with a $13.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
On January 14–15, 2026, STAAR Surgical entered into a cooperation agreement with major shareholder Broadwood Partners that triggered a broad reshaping of its board and leadership structure, including expanding the board from six to seven members, appointing Broadwood executives Neal C. Bradsher and Richard T. LeBuhn and Yunqi Capital’s Christopher Wang as new directors, and accepting the resignations of board chair Elizabeth Yeu, MD, and CEO Stephen C. Farrell from the board, with Farrell to remain chief executive until January 31, 2026 and then move into a one-year consulting role with severance and equity treatment consistent with his prior employment agreement. The agreement, which includes customary standstill and non-disparagement provisions and reimbursement of certain investor expenses, consolidates influence for STAAR’s largest shareholders—Broadwood, with 31% of the stock, and Yunqi, with 6.5%—while temporarily leaving the company out of compliance with Nasdaq’s audit committee independence requirements following Yeu’s departure, a deficiency STAAR has notified Nasdaq it intends to cure within the allowed period as the refreshed board moves to name a new chair and CEO and sharpen the company’s profitability and long-term value-creation strategy.
The most recent analyst rating on (STAA) stock is a Sell with a $21.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
On August 4, 2025, STAAR Surgical Company agreed to be acquired by Alcon Research, LLC through a merger with a subsidiary, but the companies terminated the merger agreement effective January 6, 2026, with no termination fees owed by any party and each side bearing its own transaction-related costs. At a special shareholders’ meeting held on January 6, 2026, STAAR investors, representing about 87.9% of the company’s voting power, rejected both the proposal to adopt the merger agreement and the related advisory executive compensation plan, leaving the company to continue independently rather than proceed with the previously announced transaction.
The most recent analyst rating on (STAA) stock is a Hold with a $30.75 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
On January 6, 2026, STAAR Surgical reported that preliminary voting results from a special meeting of stockholders showed the company did not receive sufficient shareholder support to approve its previously announced merger agreement with Alcon Research. As a result, STAAR intends to terminate the merger agreement without any termination fee due from either party, and will continue as an independent, publicly traded company on Nasdaq under the ticker STAA, with management reaffirming its strategy to pursue profitable sales growth, drive distribution efficiencies, and expand global adoption of its EVO ICL technology as it seeks to maximize long-term shareholder value.
The most recent analyst rating on (STAA) stock is a Hold with a $30.75 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
On December 9, 2025, STAAR Surgical Company announced an amendment to its merger agreement with Alcon Research, LLC, increasing the cash consideration for its common stock from $28.00 to $30.75 per share. The amendment also outlines the conversion of restricted stock units to Alcon shares and the elimination of certain tax indemnification arrangements, potentially enhancing shareholder value and streamlining the merger process.
The most recent analyst rating on (STAA) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
On December 8, 2025, STAAR Surgical Company announced the expiration of its go-shop period, which ended on December 6, 2025, as part of its amended merger agreement with Alcon Inc. During this period, STAAR actively solicited acquisition proposals from 21 third parties but received no competing offers, validating the effectiveness of its board’s sale process. The outcome discredits allegations from Broadwood Partners, L.P. about ignored acquisition interest, confirming Alcon as the best buyer for STAAR.
The most recent analyst rating on (STAA) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.